MAP ID="cta-BiotechNews" NAME="cta-BiotechNews">
Regulatory News :
Mauna Kea Technologies (Paris:MKEA) (NYSE Euronext: MKEA, FR0010609263), leader in the optical biopsy market and developer of Cellvizio®, today reported its full financial results for the first half of this fiscal year, ended June 30, 2013 and approved by the Board on August 30th.
Help employers find you! Check out all the jobs and post your resume.
Regulatory News :
Mauna Kea Technologies (Paris:MKEA) (NYSE Euronext: MKEA, FR0010609263), leader in the optical biopsy market and developer of Cellvizio®, today reported its full financial results for the first half of this fiscal year, ended June 30, 2013 and approved by the Board on August 30th.
Help employers find you! Check out all the jobs and post your resume.
